<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MARQIBO- vincristine sulfate 
			 </strong><br>Talon Therapeutics, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Marqibo<span class="Sup">®</span> (vinCRIStine sulfate LIPOSOME injection) safely and effectively.  See Full Prescribing Information for Marqibo (vinCRIStine sulfate LIPOSOME injection).<br><br>Marqibo<span class="Sup">®</span> (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion<br>Initial U.S. Approval: 2012</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<ul class="Disc">
<li><span class="Bold">For Intravenous Use Only – Fatal if Given by Other Routes (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has occurred with intrathecal use</span></li>
<li><span class="Bold">Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection.  Verify drug name and dose prior to preparation and administration to avoid overdosage.</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<ul class="Disc">
<li><span class="Bold">For Intravenous Use Only – Fatal if Given by Other Routes (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has occurred with intrathecal use</span></li>
<li><span class="Bold">Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection.  Verify drug name and dose prior to preparation and administration to avoid overdosage.</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Marqibo is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (ALL) in second or greater relapse or whose disease has progressed following two or more anti-<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> therapies.  This indication is based on overall response rate.  Clinical benefit such as improvement in overall survival has not been verified (<a href="#s1.1">1.1</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Intravenous use only.  Do not administer by any other route (<a href="#s2">2</a>)</span> </p>
<p class="Highlighta">Administer Marqibo at a dose of 2.25 mg/m<span class="Sup">2</span> intravenously over 1 hour once every 7 days (<a href="#s2.1">2.1</a>). </p>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">The final drug product is prepared on site from the components in the Marqibo Kit.  After preparation, each single-dose vial of Marqibo (vinCRIStine sulfate LIPOSOME injection) contains 5 mg/31 mL (0.16 mg/mL) vincristine sulfate (<a href="#s2.3.2">2.3.2</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome (<a href="#s4">4</a>)</li>
<li>Marqibo is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to vincristine sulfate or any of the other components of  Marqibo (vinCRIStine sulfate LIPOSOME injection) (<a href="#s4">4</a>)</li>
<li>Marqibo is contraindicated for intrathecal administration (<a href="#s4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Intrathecal administration is fatal (<a href="#s5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> causes tissue injury (<a href="#s5.2">5.2</a>) </li>
<li>Neurologic toxicity:  Monitor patients for peripheral motor and sensory, central and <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, and reduce, interrupt, or discontinue dosing.  Patients with preexisting severe <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> should be treated with Marqibo only after careful risk-benefit assessment (<a href="#s2.2">2.2</a>, <a href="#s5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:  Monitor blood counts prior to each dose of Marqibo.  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> may occur; consider Marqibo dose reduction or interruption and supportive care measures (<a href="#s5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span>:  Anticipate, monitor for, and manage (<a href="#s5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and/or <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>:  Institute a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> bowel regimen to prevent potential <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and/or <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> (<a href="#s5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>:  Severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> can occur (<a href="#s5.7">5.7</a>)</li>
<li>Hepatic toxicity:  Monitor liver function and modify or interrupt dosing (<a href="#s5.8">5.8</a>)</li>
<li>Embryofetal toxicity:  Can cause fetal harm.  Advise women of potential risk to the fetus (<a href="#s5.9">5.9</a>, <a href="#s8.1">8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly reported adverse reactions (incidence ≥ 30%) in clinical studies include <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (<a href="#s6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Talon Therapeutics at 1-888 292 9617 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Marqibo is expected to interact with drugs known to interact with non-liposomal vincristine sulfate (<a href="#s7">7</a>). </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pediatric Use:  The safety and effectiveness of Marqibo in pediatric patients has not been established (<a href="#s8.4">8.4</a>) </p></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Adult ALL in Second or Greater Relapse</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose modifications:  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Preparation and Handling</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	For Intravenous Use Only</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> Tissue Injury</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Neurologic Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Hepatic Toxicity</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Embryofetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Safety Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	CYP3A Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	P-glycoprotein Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1	Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<ul class="Disc">
<li><span class="Bold">For Intravenous Use Only – Fatal if Given by Other Routes [<span class="Italics">see <a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has occurred with intrathecal administration.</span></li>
<li><span class="Bold">Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection.  Verify drug name and dose prior to preparation and administration to avoid overdosage.</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Adult ALL in Second or Greater Relapse</h2>
<p class="First">Marqibo<span class="Sup">®</span> is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (ALL) in second or greater relapse or whose disease has progressed following two or more anti-<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> therapies.  This indication is based on overall response rate.  Clinical benefit such as improvement in overall survival has not been verified.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For Intravenous Use Only.  Fatal if Given by Other Routes.</p>
<p>Marqibo (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vincristine sulfate injection.  Verify drug name and dose prior to preparation and administration to avoid overdosage.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosage</h2>
<p class="First">The recommended dose of Marqibo is 2.25 mg/m<span class="Sup">2</span> intravenously over 1 hour once every 7 days.</p>
<p>Marqibo is liposome-encapsulated vincristine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose modifications:  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<p class="First">Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome [<span class="Italics">see <a href="#s4">Contraindications (4)</a></span>].  Patients with preexisting severe <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> should be treated with Marqibo only after careful risk-benefit assessment <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a></span>].  For dose or schedule modifications guidelines for patients who experience <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, see <a href="#table1">Table 1</a>.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1.	Recommended Dose Modifications for Marqibo-related <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Severity of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span> Signs and Symptoms<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="left" valign="bottom">Modification of Dose and Regimen</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Grading based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Self-care ADL:  refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Instrumental ADL:  refers to preparing meals, shopping for groceries and clothes, using telephone, managing money, etc.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">If the patient develops Grade 3 (severe symptoms; limiting self-care activities of daily living [ADL]<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>) or persistent Grade 2 (moderate symptoms; limiting instrumental ADL<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>) <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>:</td>
<td align="left">
<p class="First">Interrupt Marqibo.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> remains at Grade 3 or 4, discontinue Marqibo.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> recovers to Grade 1 or 2, reduce the Marqibo dose to 2 mg/m<span class="Sup">2</span>.</p>
</td>
</tr>
<tr class="Botrule">
<td align="left">If the patient has persistent Grade 2 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> after the first dose reduction to 2 mg/m<span class="Sup">2</span>:</td>
<td align="left">
<p class="First">Interrupt Marqibo for up to 7 days.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> increases to Grade 3 or 4, discontinue Marqibo.</p>
<p>If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> recovers to Grade 1, reduce the Marqibo dose to 1.825 mg/m<span class="Sup">2</span>.</p>
</td>
</tr>
<tr class="Last">
<td align="left">If the patient has persistent Grade 2 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> after the second dose reduction to 1.825 mg/m<span class="Sup">2</span>:</td>
<td align="left">
<p class="First">Interrupt Marqibo for up to 7 days.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> increases to Grade 3 or 4, discontinue Marqibo.</p>
<p>If the toxicity recovers to Grade 1, reduce the Marqibo dose to 1.5 mg/m<span class="Sup">2</span>.</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Preparation and Handling</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3.1"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">2.3.1	Items Required by the Pharmacy to Prepare Marqibo</span></p>
<ul class="Disc">
<li>Marqibo Kit</li>
<li>Water bath<a name="footnote-reference-4" href="#footnote-4" class="Sup">1</a>
</li>
<li>Calibrated thermometer<a href="#footnote-4" class="Sup">1</a> (0°C to 100°C)</li>
<li>Calibrated electronic timer<a href="#footnote-4" class="Sup">1</a>
</li>
<li>Sterile venting needle or other suitable device equipped with a sterile 0.2 micron filter</li>
<li>1 mL or 3 mL sterile syringe with needle, and </li>
<li>5 mL sterile syringe with needle.</li>
</ul>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">1</a></dt>
<dd>The manufacturer will provide the water bath, calibrated thermometer, and calibrated electronic timer to the medical facility at the initial order of Marqibo and will replace them every 2 years.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3.2"></a><a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Bold Italics">2.3.2	Preparation Instructions for Marqibo (vinCRIStine sulfate LIPOSOME injection), 5 mg/31 mL (0.16 mg/mL)</span></p>
<p>Procedures for handling and disposal of anticancer drugs should be followed [<span class="Italics">see <a href="#s15">References (15)</a></span>].</p>
<p>Call [1 888 292 9617] if you have questions about the preparation of Marqibo.  Marqibo takes approximately 60 to 90 minutes to prepare.  The preparer should have dedicated uninterrupted time to prepare Marqibo due to the extensive monitoring of temperature and time required for the preparation.</p>
<p>Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in Marqibo.  The preparation steps of Marqibo that involve mixing the Sodium Phosphate Injection, Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection, and VinCRIStine Sulfate Injection must be done in a <span class="Underline">biological safety cabinet</span> or by <span class="Underline">established pharmacy safety procedures for the preparation of sterile injectable formulations and hazardous drugs</span>.  However, the preparation steps that involve placement of the vial in the water bath must be done outside of the sterile area.</p>
<p>Do not use with in-line filters.  Do not mix with other drugs.</p>
<ol class="Arabic">
<li>Fill a water bath with water to a level of at least 8 cm (3.2 inches) measured from the bottom and maintain this minimum water level throughout the procedure.  The water bath must remain outside of the sterile area.</li>
<li>Place a calibrated thermometer in the water bath to monitor water temperature and leave it in the water bath until the procedure has been completed.</li>
<li>Preheat water bath to 63°C to 67°C.  Maintain this water temperature until completion of the procedure using the calibrated thermometer.</li>
<li>Visually inspect each vial in the Marqibo Kit for particulate matter and discoloration prior to preparation, whenever solution and container permit.  Do not use if a precipitate or foreign matter is present.</li>
<li>Remove all the caps on the vials and swab the vials with sterile alcohol pads.</li>
<li>Vent the Sodium Phosphate Injection vial with a sterile venting needle equipped with a sterile 0.2 micron filter or other suitable venting device in the biological safety cabinet.  Always position venting needle point well above liquid level before adding Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection and VinCRIStine Sulfate Injection.</li>
<li>Withdraw 1 mL of Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection.</li>
<li>Inject 1 mL of Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection into the Sodium Phosphate Injection vial.</li>
<li>Withdraw 5 mL of VinCRIStine Sulfate Injection.</li>
<li>Inject 5 mL of VinCRIStine Sulfate Injection into the Sodium Phosphate Injection vial.</li>
<li>Remove the venting needle and gently invert the Sodium Phosphate Injection vial 5 times to mix.  DO NOT SHAKE.</li>
<li>Fit Flotation Ring around the neck of the Sodium Phosphate Injection vial.</li>
<li>Confirm that the water bath temperature is at 63°C to 67°C using the calibrated thermometer.  Remove the Sodium Phosphate Injection vial containing VinCRIStine Sulfate Injection, Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection, and Sodium Phosphate Injection from the biological safety cabinet and place into the water bath for 10 minutes using the calibrated electronic timer.  Monitor the temperature to ensure the temperature is maintained at 63°C to 67°C.</li>
<li>IMMEDIATELY after placing the Sodium Phosphate Injection vial into the water bath, record the constitution start time and water temperature on the Marqibo Overlabel.</li>
<li>At the end of the 10 minutes, confirm that the water temperature is 63°C to 67°C using the calibrated thermometer.  Remove the vial from the water bath (use tongs to prevent <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>) and remove the Flotation Ring.</li>
<li>Record the final constitution time and the water temperature on the Marqibo Overlabel.</li>
<li>Dry the exterior of the Sodium Phosphate Injection vial with a clean paper towel, affix Marqibo (vinCRIStine sulfate LIPOSOME injection) Overlabel, and gently invert 5 times to mix. DO NOT SHAKE.</li>
<li>Permit the constituted vial contents to equilibrate for at least 30 minutes to controlled room temperature (15°C to 30°C, 59°F to 86°F).</li>
<li>Marqibo (vinCRIStine sulfate LIPOSOME injection) contains 5 mg/31 mL (0.16 mg/mL) vincristine sulfate.  ONCE PREPARED, STORE AT CONTROLLED ROOM TEMPERATURE (15°C to 30°C, 59°F to 86°F) FOR NO MORE THAN 12 HOURS.</li>
<li>Swab the top of the vial now containing Marqibo with a sterile alcohol pad and return the vial back into the biological safety cabinet.</li>
<li>Calculate the patient's Marqibo dose based on the patient's actual body surface area (BSA) and remove the volume corresponding to the patient's Marqibo dose from an infusion bag containing 100 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.</li>
<li>Inject the dose of Marqibo into the infusion bag to result in a final volume of 100 mL.</li>
<li>Complete the information required on the Infusion Bag Label and apply to the infusion bag.</li>
<li>Finish administration of the diluted product within 12 hours of the initiation of Marqibo preparation.</li>
<li>Empty, clean, and dry the water bath after each use.</li>
<li>Deviations in temperature, time, and preparation procedures may fail to ensure proper encapsulation of vincristine sulfate into the liposomes.  In the event that the preparation deviates from the instructions in the above steps, the components of the kit should be discarded and a new kit should be used to prepare the dose.</li>
</ol>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Do not use if a precipitate or foreign matter is present.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Marqibo is prepared from the components in the Marqibo Kit.  Following the preparation procedure according to section <a href="#s2.3.2">2.3.2</a>, each single-dose vial of Marqibo (vinCRIStine sulfate LIPOSOME injection) contains 5 mg/31 mL (0.16 mg/mL) vincristine sulfate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.</p>
<p>Marqibo is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).</p>
<p>Marqibo is contraindicated for intrathecal administration.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	For Intravenous Use Only</h2>
<p class="First">Fatal if Given by Other Routes.  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has occurred with intrathecal use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> Tissue Injury</h2>
<p class="First">Only administer through a secure and free-flowing venous access line.  If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is suspected, discontinue infusion immediately and consider local treatment measures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Neurologic Toxicity</h2>
<p class="First">Sensory and motor neuropathies are common and are cumulative.  Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, such as <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>, <span class="product-label-link" type="condition" conceptid="4290597" conceptname="Absent reflex">areflexia</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="4036155" conceptname="Decreased vibratory sense">decreased vibratory sense</span>, <span class="product-label-link" type="condition" conceptid="441848" conceptname="Cranial nerve disorder">cranial neuropathy</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, both before and during treatment.  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may occur.  The risk of neurologic toxicity is greater if Marqibo is administered to patients with preexisting neuromuscular disorders or when other drugs with risk of neurologic toxicity are being given.  In the studies of relapsed and/or refractory adult ALL patients, Grade ≥ 3 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> events occurred in 32.5% of patients.  Worsening <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> requires dose delay, reduction, or discontinuation of Marqibo [<span class="Italics">see <a href="#s2.2">Dosage and Administration (2.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Monitor complete blood counts prior to each dose of Marqibo.  If Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> develops, consider Marqibo dose modification or reduction as well as supportive care measures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> (TLS) may occur in patients with ALL receiving Marqibo.  Anticipate, monitor for, and manage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and colonic pseudo-obstruction have occurred.  Marqibo can cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> [<span class="Italics">see <a href="#s6">Adverse Reactions (6)</a></span>].  Institute a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> bowel regimen to mitigate potential <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and/or <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, considering adequate dietary fiber intake, hydration, and routine use of stool softeners, such as docusate.  Additional treatments, such as senna, bisacodyl, milk of magnesia, magnesium citrate, and lactulose may be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></h2>
<p class="First">Marqibo can cause severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.  Marqibo dose delay, reduction, or discontinuation may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Hepatic Toxicity</h2>
<p class="First">Fatal liver toxicity and elevated levels of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> have occurred.  Elevated levels of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> of Grade ≥3 occurred in 6-11% of patients in clinical trials.  Monitor hepatic function tests.  Reduce or interrupt Marqibo for hepatic toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Embryofetal Toxicity</h2>
<p class="First">Marqibo can cause fetal harm when administered to a pregnant woman.  Vincristine sulfate liposome injection was teratogenic or caused embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> in animals.  Women of childbearing potential should avoid becoming pregnant while being treated with Marqibo.  There are no adequate and well-controlled studies of Marqibo in pregnant women and there were no reports of pregnancy in any of the clinical studies in the Marqibo clinical development program.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see <a href="#s8.1">Use in Specific Populations (8.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are also discussed in other sections of the labeling:</p>
<ul class="Disc">
<li>For intravenous use only [<span class="Italics">see <a href="#s5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> tissue injury [<span class="Italics">see <a href="#s5.2">Warnings and Precautions (5.2)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span> [<span class="Italics">see <a href="#s5.3">Warnings and Precautions (5.3)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> [<span class="Italics">see <a href="#s5.4">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> [<span class="Italics">see <a href="#s5.5">Warnings and Precautions (5.5)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> [<span class="Italics">see <a href="#s5.6">Warnings and Precautions (5.6)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> [<span class="Italics">see <a href="#s5.7">Warnings and Precautions (5.7)</a></span>]</li>
<li>Hepatic toxicity [<span class="Italics">see <a href="#s5.8">Warnings and Precautions (5.8)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Safety Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics Underline">Integrated Summary of Safety in Relapsed and/or Refractory Ph- Adult <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span></span></p>
<p>Marqibo, at a dose of 2.25 mg/m<span class="Sup">2</span> weekly, was studied in a total of 83 patients in two trials: study 1 and study 2.  Adverse reactions were observed in 100% of patients.  The most common adverse reactions (&gt;30%) were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (57%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (52%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (43%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (41%), <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (39%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (38%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (37%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (34%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (33%), and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (32%).</p>
<p>Adverse reactions of Grade 3 or greater were reported in 96% of patients.  Adverse reactions of Grade 3 or greater and occurring in ≥ 5% of patients are summarized in <a href="#table2">Table 2</a>.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2.	Most Commonly Reported (&gt; 5%) Grade <a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> 3 or Greater Adverse Reactions among 83 Patients Receiving the Clinical Dosing Regimen</span></caption>
<col align="left" valign="middle" width="80%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th align="left">Adverse Reactions Grade ≥ 3</th>
<th align="center">Study 1 and 2<br>(N=83)<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>-associated adverse reactions.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Blood and Lymphatic System Disorders</span></td>
<td align="center"><span class="Italics">47 (56.6)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></td>
<td align="center">26 (31.3)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center">15 (18.1)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">14 (16.9)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center">14 (16.9)</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></td>
<td align="center"><span class="Italics">33 (39.8)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td align="center">7 (8.4)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">Septic Shock</span></td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4327861" conceptname="Bacteremia due to Staphylococcus aureus">Staphylococcal Bacteremia</span></td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></span></td>
<td align="center"><span class="Italics">27 (32.5)</span></td>
</tr>
<tr>
<td align="left">  Peripheral Sensory and Motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td align="center">14 (16.7)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">4 (4.8)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, Colonic Pseudo-Obstruction</td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">4 (4.8)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular Weakness</span></td>
<td align="center">1 (1.2)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Respiratory Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="center"><span class="Italics">17 (20.5)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">Respiratory Distress</span></td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span></td>
<td align="center">4 (4.8)</td>
</tr>
<tr>
<td align="left"><span class="Italics">General Disorders and Administration Site Condition</span></td>
<td align="center"><span class="Italics">31 (37.3)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">12 (14.5)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">10 (12.0)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center">7 (8.4)</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"><span class="Italics">21 (25.3)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">7 (8.4)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Investigations</span></td>
<td align="center"><span class="Italics">20 (24.1)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate Aminotransferase</span> Increased</td>
<td align="center">6 (7.2)</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center"><span class="Italics">8 (9.6)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Psychiatric Disorders</span></td>
<td align="center"><span class="Italics">9 (10.8)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">Mental Status Changes</span></td>
<td align="center">3 (3.6)</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td align="center"><span class="Italics">9 (10.8)</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac Arrest</span></td>
<td align="center">5 (6.0)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Renal and Urinary Disorders</span></td>
<td align="center"><span class="Italics">6 (7.2)</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td align="center"><span class="Italics">7 (8.4)</span></td>
</tr>
</tbody>
</table>
<p>A total of 75.9% of patients experienced serious adverse events (SAEs) during the studies.  The most commonly reported SAEs included <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (20.5%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (13.3%), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (7.2%), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> (6.0%), and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (6.0%).</p>
<p>Dose reduction, delay, or omission occurred in 53% of patients during the treatment.</p>
<p>Twenty-eight percent of patients experienced adverse reactions leading to treatment discontinuation.  The most common adverse reactions that caused treatment discontinuation were <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (10%), <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>-related (7%), and <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> (2%).</p>
<p>Adverse reactions related to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> and leading to treatment discontinuation were <span class="product-label-link" type="condition" conceptid="4036155" conceptname="Decreased vibratory sense">decreased vibratory sense</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial palsy</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, each reported in at least 1 patient.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> occurred in 23% of patients in study 1.  The non-<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> related causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were brain infarct (1), <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhage</span> (2), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> (1), multi system organ failure (2), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> (3), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (4), <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span> (1), and <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span> (1).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies have been conducted with Marqibo.  Marqibo is expected to interact with drugs known to interact with non-liposomal vincristine sulfate.</p>
<p>Simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included non-liposomal vincristine sulfate have been reported to reduce blood levels of phenytoin and to increase <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1	CYP3A Interactions</h2>
<p class="First">Vincristine sulfate, the active agent in Marqibo, is a substrate for cytochrome P450 3A isozymes (CYP3A); therefore, the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin).  Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's Wort).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2	P-glycoprotein Interactions</h2>
<p class="First">Vincristine sulfate, the active agent in Marqibo, is also a substrate for P-glycoprotein (P-gp).  The effect of concomitant use of potent P-gp inhibitors or inducers has not been investigated; it is likely that these agents will alter the pharmacokinetics or pharmacodynamics of Marqibo.  Therefore the concomitant use of potent P-gp inhibitors or inducers should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category D [<span class="Italics">see <a href="#s5.9">Warnings and Precautions (5.9)</a></span>]</p>
<p>Based on its mechanism of action and findings from animal studies, Marqibo can cause fetal harm when administered to pregnant women.</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.  In an embryofetal developmental study, pregnant rats were administered vincristine sulfate liposome injection intravenously during the period of organogenesis at vincristine sulfate doses of 0.022 to 0.09 mg/kg/day.  Drug-related adverse effects included <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (skeletal and visceral), decreases in fetal weights, increased numbers of early resorptions and post-implantation losses, and decreased maternal body weights  Malformations were observed at doses ≥ 0.044 mg/kg/day in animals at systemic exposures approximately 20-40% of those reported in patients at the recommended dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Marqibo in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Safety and effectiveness in elderly individuals have not been established.  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The influence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the safety, efficacy, and pharmacokinetics of Marqibo has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Non-liposomal vincristine sulfate is excreted primarily by the liver.  The influence of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the safety and efficacy of Marqibo has not been evaluated.</p>
<p>The pharmacokinetics of Marqibo was evaluated in patients with moderate hepatic dysfunction (Child-Pugh B) secondary to melanoma liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.  The dose-adjusted maximum plasma concentration (C<span class="Sub">max</span>) and area under the concentration-time curve (AUC) of Marqibo in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was comparable to the C<span class="Sub">max</span> and AUC of patients with ALL who had otherwise normal hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">When Marqibo (vinCRIStine sulfate LIPOSOME injection) was administered at a dose of 2.4 mg/m<span class="Sup">2</span>, severe toxicities including motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> of Grade 3, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span> of Grade 4, and elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> of Grade 4 were reported in 1 patient each.  There is no known antidote for overdosage.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Marqibo (vinCRIStine sulfate LIPOSOME injection) is vincristine encapsulated in sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> liposomes for intravenous administration.</p>
<p>The active ingredient in Marqibo is vincristine sulfate.  Vincristine sulfate is a vinca alkaloid isolated as a 1:1 sulfate salt from the periwinkle plant (<span class="Italics">Catharanthus roseus</span>).  It is a hygroscopic, white to slightly yellowish crystalline powder that is soluble in water.  It has a molecular weight of 923.04 (salt form) / 824.98 (base form) and a molecular formula of C<span class="Sub">46</span>H<span class="Sub">56</span>N<span class="Sub">4</span>O<span class="Sub">10</span> • H<span class="Sub">2</span>SO<span class="Sub">4</span>.  The chemical name for vincristine sulfate is 22-oxovincaleukoblastine and it has the following chemical structure:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e&amp;name=marqibo-01.jpg"></p>
<p>Vincristine is encapsulated in a Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> liposome.  The lipid components in the liposome are sphingomyelin and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> at a molar ratio of approximately 60:40 (mol:mol).</p>
<p>After preparation, each vial of Marqibo contains 5 mg vincristine sulfate, 500 mg mannitol, 73.5 mg sphingomyelin, 29.5 mg <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, 36 mg sodium citrate, 38 mg citric acid, 355 mg sodium phosphate, and 225 mg sodium chloride.</p>
<p>Marqibo (vinCRIStine sulfate LIPOSOME injection) appears as a white to off-white, translucent suspension, essentially free of visible foreign matter and aggregates, comprised of sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> liposomes, with an approximate liposome mean diameter of 100 nm.  Greater than 95% of the drug is encapsulated in the liposomes.</p>
<p>The Marqibo Kit component vials for the preparation of Marqibo (vinCRIStine sulfate LIPOSOME injection) include:</p>
<ul class="Disc">
<li>VinCRIStine Sulfate Injection, USP (5 mg/5 mL).  Each VinCRIStine Sulfate Injection vial consists of 5 mg/5 mL vincristine sulfate (which is equivalent to 4.5 mg/5 mL vincristine free base) and 500 mg/5 mL mannitol.</li>
<li>Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection (103 mg/mL).  Each Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection vial consists of 73.5 mg/mL sphingomyelin, 29.5 mg/mL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, 33.6 mg/mL citric acid, 35.4 mg/mL sodium citrate, and not more than 0.1% ethanol.</li>
<li>Sodium Phosphate Injection (355 mg/25 mL).  Each Sodium Phosphate Injection vial consists of 355 mg/25 mL dibasic sodium phosphate and 225 mg/25 mL sodium chloride.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Marqibo is a sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> liposome-encapsulated formulation of vincristine sulfate.  Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting in altered microtubule structure and function.  Non-liposomal vincristine sulfate stabilizes the spindle apparatus, preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The plasma pharmacokinetics of Marqibo was investigated in 13 adult patients with relapsed ALL who received a Marqibo dose of 2.25 mg/m<span class="Sup">2</span> administered as a 1-hour intravenous infusion.  The calculated pharmacokinetic parameters for total plasma vincristine sulfate are given in <a href="#table3">Table 3</a>.  The vincristine sulfate levels reported in <a href="#table3">Table 3</a> reflect liposome-encapsulated drug that may not be immediately bioavailable and may not be directly comparable to plasma levels of vincristine sulfate after administration of non-liposomal vincristine sulfate, which is immediately bioavailable.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3.	Pharmacokinetic Parameters from Patients with <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> Treated with 2.25 mg/m<span class="Sup">2</span> Marqibo<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead><tr class="First Last">
<th align="left">Variable</th>
<th align="center">N</th>
<th align="center">Mean</th>
<th align="center">SE</th>
<th align="center">Median</th>
<th align="center">Range</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Dose was administered as a 1-hour infusion.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">AUC<span class="Sub">∞ </span>(h∙ng/mL)</td>
<td align="center">13</td>
<td align="center">14566</td>
<td align="center">1766</td>
<td align="center">13680</td>
<td align="center">7036-26074</td>
</tr>
<tr>
<td align="left">CL (mL/h)</td>
<td align="center">12</td>
<td align="center">345</td>
<td align="center">100</td>
<td align="center">302</td>
<td align="center">148-783</td>
</tr>
<tr class="Last">
<td align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td align="center">13</td>
<td align="center">1220</td>
<td align="center">64</td>
<td align="center">1230</td>
<td align="center">919-1720</td>
</tr>
</tbody>
</table>
<p>The plasma clearance (CL) of Marqibo is slow, 345 mL/h, at a dose of 2.25 mg/m<span class="Sup">2</span>.  This is in comparison to the rapid clearance of non-liposomal vincristine sulfate at 189 mL/min/m<span class="Sup">2</span> (11,340 mL/h).  The slow clearance of Marqibo contributes to a much higher AUC for Marqibo relative to non-liposomal vincristine sulfate.</p>
<p>Following intravenous administration of Marqibo, urinary excretion was a minor route of elimination for vincristine sulfate and its metabolite.  Less than 8% of the administered Marqibo dose was eliminated in urine over a 96-hour observation period, which is similar to the urinary excretion of non-liposomal vincristine sulfate.  Following non-liposomal vincristine sulfate infusion, the main route of vincristine sulfate excretion was the fecal route, accounting for 69% of the administered dose over 72 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been conducted with Marqibo or non-liposomal vincristine sulfate.  Based on the mechanism of action and genotoxicity findings in nonclinical studies conducted with non-liposomal vincristine sulfate, Marqibo may be carcinogenic.</p>
<p>No genotoxicity studies have been conducted with Marqibo.  Non-liposomal vincristine was genotoxic in some <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> studies.</p>
<p>The single- and repeat-dose animal toxicology study results indicate that Marqibo can impair male fertility, consistent with the literature on non-liposomal vincristine sulfate.  Administration of vincristine liposome injection causes testicular degeneration and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and epididymal <span class="product-label-link" type="condition" conceptid="40492473" conceptname="Aspermia">aspermia</span> in rats.</p>
<p>Gonadal dysfunction has been reported in both male and female post-pubertal patients who received multi-agent chemotherapy including non-liposomal vincristine sulfate.  The degree to which testicular or ovarian functions are affected is age-, dose-, and agent-dependent.  Recovery may occur in some but not all patients.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">In a repeat-dose comparative toxicology study in rats, vincristine sulfate liposome injection or non-liposomal vincristine sulfate was administered to animals intravenously once per week for 6 weeks.  Clinical signs of toxicity consistent with <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> were greater with vincristine sulfate liposome injection than with non-liposomal vincristine sulfate at equal vincristine sulfate doses of 2 mg/m<span class="Sup">2</span>/week and included uncoordinated movements, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, reduced muscle tone, and limited usage of the limbs.  Neurological testing indicated drug-induced peripheral <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> with both drugs.  Based on the histopathology examination after 6 weekly doses, vincristine sulfate liposome injection induced greater peripheral <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> (nerve fiber degeneration) and secondary skeletal <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle atrophy</span> than the equal dose of non-liposomal vincristine sulfate.  In a separate tissue distribution study in rats, administration of 2 mg/m<span class="Sup">2</span> of intravenous liposomal or non-liposomal vincristine sulfate showed greater accumulation of vincristine sulfate in sciatic and tibial nerves (as well as the lymph nodes, spleen, and bone marrow) of the animals following vincristine sulfate liposome injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span></h2>
<p class="First">Marqibo was studied in an international, open-label, multi-center, single-arm trial (Study 1).  Eligible patients were 18 years of age or older with Philadelphia chromosome negative ALL in second or greater relapse or whose disease progressed after two or greater treatment lines of anti-<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> therapy.  Patients had to have achieved a complete remission (CR) to at least one prior anti-<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> chemotherapy, defined by a <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>-free interval of equal or more than 90 days.  Patients were not eligible for immediate hematopoietic stem cell transplantation (HSCT) at the time of screening and enrollment.</p>
<p>Patients received intravenous Marqibo monotherapy at 2.25 mg/m<span class="Sup">2</span> over 60 minutes every 7 days.  Concomitant corticosteroids were not permitted beyond Day 5.</p>
<p>The treated population included 65 patients who received at least 1 dose of Marqibo.  All of the treated patients had received prior vincristine sulfate and 80% had evidence of residual <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> at study baseline.  Among treated patients, 51% were male, 86% were white, 45% were under 30 years of age, 11% were age 65 or older, 48% had undergone prior HSCT, 51% had received 3 or more prior therapies, and 45% were refractory to their immediate prior therapy.  Disease characteristics were 85% precursor B-cell ALL and 15% precursor T-cell ALL.  In addition, 22 of 65 (34%) treated patients did not receive asparaginase products prior to enrollment.  Efficacy results are shown in <a href="#table4">Table 4</a>.</p>
<a name="table4"></a><table width="85%">
<caption><span>Table 4.	Study 1 Results</span></caption>
<col align="left" valign="top" width="55%">
<col align="center" valign="top" width="45%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Study 1<br>(N=65)<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>CI = Confidence interval (Clopper-Pearson).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left">Complete remission (CR)</td>
<td align="center">3 (4.6)</td>
</tr>
<tr class="Botrule">
<td align="left">CR with incomplete blood count recovery (CRi)</td>
<td align="center">7 (10.8)</td>
</tr>
<tr>
<td align="left">  CR + CRi</td>
<td align="center">10 (15.4)</td>
</tr>
<tr class="Botrule">
<td align="left">  (95% CI<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>)</td>
<td align="center">(7.6 – 26.5)</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Bold">MEDIAN DURATION of CR or CRi:</span></td>
<td align="center"><span class="Bold">Days (95% CI)</span></td>
</tr>
<tr class="Botrule">
<td align="left">Based on the first date of CR or CRi to the date of the last available histologic assessment of the same response (n=8) </td>
<td align="center">28 (7, 36)</td>
</tr>
<tr class="Last">
<td align="left">Based on the first date of CR or CRi to date of documented relapse, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or subsequent chemotherapies including hematopoietic stem cell transplant (HSCT) (n=10)</td>
<td align="center">56 (9, 65)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposure to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. (2006) 63:1172-1193.</li>
<li>Polovich M, White JM, Kelleher LO (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">The Marqibo Kit (NDC # 20536-322-01) contains:</p>
<ul class="Disc">
<li>Vial containing VinCRIStine Sulfate Injection, USP 5 mg/5 mL (1 mg/mL) – NDC # 20536-323-01</li>
<li>Vial containing Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection 103 mg/mL – NDC # 20536-324-01</li>
<li>Vial containing Sodium Phosphate Injection 355 mg/25 mL (14.2 mg/mL) – NDC # 20536-325-01</li>
<li>Flotation Ring</li>
<li>Overlabel for Sodium Phosphate Injection vial containing constituted Marqibo (vinCRIStine sulfate LIPOSOME injection), 5 mg/31 mL (0.16 mg/mL)</li>
<li>Infusion Bag Label</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>16.1	Storage</h2>
<p class="First"><span class="Bold">Store the Marqibo Kit in the refrigerator at 2°C to 8°C – Do Not Freeze</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians are advised to discuss the following with patients prior to treatment with Marqibo:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> Tissue Injury:</span>  Advise patients to report immediately any burning or local irritation during or after the infusion [<span class="Italics">see <a href="#s5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<p class="First"><span class="Bold">Ability to Drive or Operate Machinery or Impairment of Mental Ability:</span>  Marqibo may cause <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.  Advise patients not to drive or operate machinery if they experience any of these symptoms [<span class="Italics">see <a href="#s5.3">Warnings and Precautions (5.3</a>, <a href="#s5.7">5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal/<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>:</span>  Patients receiving Marqibo may experience <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.  Advise patients how to avoid <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> by a diet high in bulk fiber, fruits and vegetables, and adequate fluid intake as well as use of a stool softener, such as docusate.  Instruct patients to seek medical advice if they experience symptoms of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> such bowel movement infrequency, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> [<span class="Italics">see <a href="#s5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy/Nursing:</span>  Advise patients to use effective contraceptive measures to prevent pregnancy during treatment with Marqibo [<span class="Italics">see <a href="#s5.9">Warnings and Precautions (5.9)</a></span>].  Instruct patients to report pregnancy to their physicians immediately.  Advise patients that they should not receive Marqibo while pregnant or breastfeeding.  If a patient wishes to re-start breastfeeding after treatment, she should be advised to discuss the appropriate timing with her physician [<span class="Italics">see <a href="#s8.3">Use in Specific Populations (8.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<p class="First"><span class="Bold">Concomitant Medications:</span>  Advise patients to speak with their physicians about any other medication they are currently taking [<span class="Italics">see <a href="#s7">Drug Interactions (7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>:</span>  Advise patients to contact their physicians if they experience new or worsening symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, a burning feeling in the feet or hands, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the feet or hands [<span class="Italics">see <a href="#s5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<p class="First"><span class="Bold">Other:</span>  Instruct patients to notify their physicians if they experience <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span>, or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> [<span class="Italics">see <a href="#s5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Manufactured by:</span><br>VinCRIStine Sulfate Injection, USP<br>Hospira Australia Pty Ltd<br>Mulgrave, Victoria 3170<br>Australia</p>
<p>Sphingomyelin/<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection<br>Cangene Corporation<br>Winnipeg, Manitoba R3T 5Y3<br>Canada</p>
<p>Sodium Phosphate Injection<br>Jubilant HollisterStier<br>Spokane, WA 99207</p>
<p>Marqibo Kit for the Preparation of vinCRIStine sulfate LIPOSOME injection<br>Anderson Packaging, Inc<br>Rockford, IL 61109</p>
<p><span class="Bold">Distributed by:</span><br>Talon Therapeutics, Inc.<br>400 Oyster Point Boulevard, Suite 200<br>South San Francisco, CA 94080</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Label</span></p>
<p><span class="Bold">NDC </span>20536-323-01</p>
<p>Rx only</p>
<p><span class="Bold">VinCRIStine Sulfate Injection, USP<br>5 mg/5 mL (1 mg/mL)</span></p>
<p>for use only in the preparation of <span class="Bold">Marqibo</span><span class="Sup">®</span></p>
<p>Single Use Vial – Discard Unused Portion</p>
<p>See package insert for preparation instructions</p>
<p>Mfg. for: Talon Therapeutics, Inc., South San Francisco, CA 94080<br>Mfg. by: Hospira Australia Pty Ltd, Mulgrave VIC 3170, Australia</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e&amp;name=marqibo-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 103 mg/mL Vial Label</span></p>
<p><span class="Bold">NDC </span>20536-324-01</p>
<p>Rx only</p>
<p><span class="Bold">Sphingomyelin-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection<br>103 mg/mL</span></p>
<p>for use only in the preparation of <span class="Bold">Marqibo</span><span class="Sup">®</span></p>
<p>Single Use Vial – Discard Unused Portion</p>
<p>See package insert for preparation instructions</p>
<p>Mfg. for: Talon Therapeutics, Inc., South San Francisco, CA 94080<br>Mfg. by: Cangene Corporation, Winnipeg, MB Canada R3T 5Y3</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 103 mg/mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e&amp;name=marqibo-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 355 mg/25 mL Vial Label</span></p>
<p><span class="Bold">NDC </span>20536-325-01</p>
<p>Rx only</p>
<p><span class="Bold">Sodium Phosphate Injection<br>355 mg/25 mL (14.2 mg/mL)</span></p>
<p>for use only in the preparation of <span class="Bold">Marqibo</span><span class="Sup">®</span></p>
<p>Single Use Vial – Discard Unused Portion</p>
<p>See package insert for preparation instructions</p>
<p>Mfg. for: Talon Therapeutics, Inc., South San Francisco, CA 94080<br>Mfg. by: Jubilant HollisterStier, Spokane, WA 99207</p>
<p>Store at 2°C to 8°C<br>(36°F to 46°F)<br><span class="Bold">DO NOT FREEZE.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 355 mg/25 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e&amp;name=marqibo-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Kit Label</span></p>
<p><span class="Bold">NDC </span>20536-322-01</p>
<p>Rx only</p>
<p><span class="Bold">Marqibo</span><span class="Sup">®</span><br>(vinCRIStine sulfate LIPOSOME injection)</p>
<p><span class="Bold">Marqibo Kit Contents:</span></p>
<ul class="Disc">
<li>Sodium Phosphate Injection Vial 355 mg/25 mL (14.2 mg/mL)</li>
<li>Sphingomyelin-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Liposome Injection Vial 103 mg/mL</li>
<li>VinCRIStine Sulfate Injection, USP Vial 5 mg/5 mL (1 mg/mL)</li>
<li>Floatation Ring</li>
<li>Overlabel and Infusion Bag Label</li>
<li>Package Insert</li>
</ul>
<p>Store kit at 2°C to 8°C (36°F to 46°F). <span class="Bold">DO NOT FREEZE.</span></p>
<p><span class="Bold">For Intravenous Use Only<br>Fatal If Given By Other Routes</span></p>
<p><span class="Bold">Single Use Vials – Discard Unsued Portion</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Kit Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e&amp;name=marqibo-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MARQIBO 		
					</strong><br><span class="contentTableReg">vincristine sulfate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:20536-322</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:20536-322-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">25 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>VINCRISTINE SULFATE 		
					</strong><br><span class="contentTableReg">vincristine sulfate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:20536-323</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Vincristine Sulfate</strong> (Vincristine) </td>
<td class="formItem">Vincristine Sulfate</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">500 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sulfuric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:20536-323-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202497</td>
<td class="formItem">01/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>SPHINGOMYELIN-CHOLESTEROL 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, citric acid monohydrate, sodium citrate, alcohol, and water injection, suspension, liposomal</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:20536-324</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:20536-324-01</td>
<td class="formItem">1 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202497</td>
<td class="formItem">01/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>SODIUM PHOSPHATE 		
					</strong><br><span class="contentTableReg">sodium phosphate, dibasic, heptahydrate, sodium chloride, and water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:20536-325</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Dibasic, Heptahydrate</strong></td>
<td class="formItem">14.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:20536-325-01</td>
<td class="formItem">25 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202497</td>
<td class="formItem">01/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202497</td>
<td class="formItem">01/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Talon Therapeutics, Inc
							(147517044)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fine Chemicals (PTY)</td>
<td class="formItem"></td>
<td class="formItem">568855923</td>
<td class="formItem">API MANUFACTURE(20536-322), ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira Australia Pty Ltd</td>
<td class="formItem"></td>
<td class="formItem">758967652</td>
<td class="formItem">MANUFACTURE(20536-322), ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene</td>
<td class="formItem"></td>
<td class="formItem">244844056</td>
<td class="formItem">MANUFACTURE(20536-322), ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Jubilant Hollister-Stier</td>
<td class="formItem"></td>
<td class="formItem">069263643</td>
<td class="formItem">MANUFACTURE(20536-322), ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nucro</td>
<td class="formItem"></td>
<td class="formItem">241266845</td>
<td class="formItem">ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PPD Development, LP</td>
<td class="formItem"></td>
<td class="formItem">838082055</td>
<td class="formItem">ANALYSIS(20536-322)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AndersonBrecon</td>
<td class="formItem"></td>
<td class="formItem">053217022</td>
<td class="formItem">LABEL(20536-322), PACK(20536-322)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a6ac9d15-6436-4c92-8c81-b16d7d0a8598</div>
<div>Set id: a1869e23-b93b-4407-843b-4b830319d82e</div>
<div>Version: 4</div>
<div>Effective Time: 20121003</div>
</div>
</div> <div class="DistributorName">Talon Therapeutics, Inc</div></p>
</body></html>
